Anemia of inflammation (AI, also known as anemia of chronic disease or ACD) is one of the most common forms of anemia, comprising up to 40% of all anemias and affecting millions of patients, including those with cancer, chronic kidney disease, and autoimmune diseases. Hepcidin is a key driver of the disease as inflammation induces excessive hepcidin production and restricts iron absorption and utilization. These forms of anemia are refractory to current treatments, but exploratory clinical studies with modest inhibitors of the hepcidin pathway have demonstrated promising effects on anemia. We believe that targeting HJV provides a uniquely selective and potent approach to suppress hepcidin and normalize iron metabolism.